Chelsea Therapeutics, Inc. Supports Initiation of Phase II Study of Droxidopa in Combination With Carbidopa in Adult Attention Deficit Hyperactivity Disorder

CHARLOTTE, N.C., Feb. 11, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, in combination with carbidopa has been initiated in adult attention deficit hyperactivity disorder (ADHD).